Stock Fundamentals

Company Information

Company Name
Omeros Corporation
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US6821431029
CIK: 0001285819
CUSIP: 682143102
Currency: USD
Full Time Employees: 175
Phone: 206 676 5000
Fiscal Year End: December
IPO Date: Oct 08, 2009
Description:

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Address:

The Omeros Building, Seattle, WA, United States, 98119

Directors & Officers

Name Title Year Born
Dr. Gregory A. Demopulos M.D. Co-Founder, Chairman, CEO & President 1959
Mr. David J. Borges VP of Finance, Chief Accounting Officer & Treasurer 1965
Mr. Peter B. Cancelmo J.D. VP, General Counsel & Corporate Secretary 1979
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder 1963
Dr. George A. Gaitanaris M.D., Ph.D. Chief Scientific Officer & VP of Science 1957
Mr. Peter W. Williams Vice President of Human Resources 1968
Dr. Catherine A. Melfi Ph.D. Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems 1959
Mr. David W. Ghesquiere VP & Chief Business Development Officer 1967

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 13, 2026 David J Borges N/A Sale 30.00K $12.31 $369.30K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.31M Mar 31, 2026 7.34% $0.00 4.88%
Vanguard Group Inc 4.01M Dec 31, 2025 5.55% $0.00 19.91%
Ingalls & Snyder LLC 3.56M Mar 31, 2026 4.92% $1.33 3.21%
Vanguard Capital Management, LLC 2.98M Mar 31, 2026 4.12% $0.00 0.00%
UBS Group AG 2.34M Mar 31, 2026 3.23% $0.00 5.30%
State Street Corp 1.92M Mar 31, 2026 2.65% $0.00 21.99%
Stifel Financial Corp 1.83M Mar 31, 2026 2.53% $0.02 1.21%
Geode Capital Management, LLC 1.75M Mar 31, 2026 2.42% $0.00 7.42%
CI Private Wealth LLC 1.38M Dec 31, 2025 1.90% $0.02 125.93%
Vanguard Portfolio Management, LLC 718.68K Mar 31, 2026 0.99% $0.00 0.00%
Charles Schwab Investment Management Inc 582.51K Mar 31, 2026 0.80% $0.00 -1.81%
Bank of Montreal 568.43K Mar 31, 2026 0.79% $0.00 -5.52%
BMO Capital Markets Corp. 568.43K Mar 31, 2026 0.79% $0.00 -5.52%
Northern Trust Corp 563.87K Mar 31, 2026 0.78% $0.00 7.05%
Vanguard Fiduciary Trust Co 492.35K Mar 31, 2026 0.68% $0.00 0.00%
Susquehanna International Group, LLP 485.03K Mar 31, 2026 0.67% $0.00 -34.62%
Millennium Management LLC 410.61K Mar 31, 2026 0.57% $0.00 -7.06%
Morgan Stanley - Brokerage Accounts 317.89K Mar 31, 2026 0.44% $0.00 -17.68%
Two Sigma Investments LLC 286.47K Mar 31, 2026 0.40% $0.00 -45.41%
Badgley Phelps Wealth Managers, LLC 263.56K Mar 31, 2026 0.36% $0.06 0.00%

Shares Statistics

Shares Outstanding: 72.38M
Shares Float: 69.79M
% Insiders: 355.70%
% Institutions: 4,442.30%
Short % Float: 23.31%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.12M 2.93% ▲ 0.00% Apr 30, 2026
2 iShares Russell 2000 ETF 1.64M 2.27% ▲ 0.93% May 29, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 798.32K 1.10% ▲ 0.52% Apr 30, 2026
4 Fidelity Small Cap Index 672.57K 0.93% ▲ 4.28% Mar 31, 2026
5 State Street® SPDR® S&P® PhrmctlsETF 535.89K 0.74% ▲ 0.00% May 31, 2026
6 iShares Russell 2000 Growth ETF 495.86K 0.69% ▼ 0.65% May 29, 2026
7 State St Russell Sm/Mid Cp® Indx SL Cl I 422.77K 0.58% ▲ 0.00% May 31, 2026
8 Russell 2000 Equity Index Fund B 413.25K 0.57% ▲ 15.85% Dec 31, 2025
9 Fidelity Extended Market Index 379.56K 0.52% ▼ 0.36% Apr 30, 2026
10 Vanguard Russell 2000 ETF 347.12K 0.48% ▲ 2.77% Apr 30, 2026

Valuation Metrics

Enterprise Value: $645.73M
Trailing P/E: 7.66
Forward P/E: 58.14

Financial Highlights

Market Cap: $632.20M
EBITDA: $-104.33M
P/E Ratio: $7.66
PEG Ratio: $0.81
Book Value: $-1.69
Earnings/Share: $1.14
Profit Margin: 871.02%
Operating Margin: -176.09%
ROA (TTM): -25.24%
ROE (TTM): -576.33%
Revenue (TTM): $9.89M
Revenue/Share (TTM): $0.15
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 14.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.76x -1.91x 1.37x -127.91x -126.58x
2024-12-31 1.69x -1.06x 1.66x -6.86x -1.23x
2023-12-31 4.09x -9.08x 1.07x -11.35x -1.58x
2022-12-31 3.25x 3.73x 0.86x -7.20x -2.02x
2021-12-31 4.79x 13.40x 0.94x -8.83x -1.87x
2020-12-31 4.12x -1.99x 1.67x -5.87x -1.43x
2019-12-31 1.87x -1.48x 1.80x -2.80x -2.69x
2018-12-31 2.41x 0.23x -0.04x -6.91x -1.23x
2017-12-31 4.12x -30.24x 1.02x -3.98x -2.03x
2016-12-31 3.75x -2.13x 1.56x -6.94x -1.36x
2015-12-31 2.29x -1.90x 1.54x -19.94x -0.70x
2014-12-31 0.50x -0.77x 4.85x -20.18x -0.47x
2013-12-31 1.25x -1.11x 2.11x -21.35x -0.55x
2012-12-31 2.65x -0.09x 9.07x -21.33x -0.55x
2011-12-31 1.37x -3.50x 1.21x -14.55x -0.74x
2010-12-31 2.76x 0.48x 0.55x -19.61x -0.36x
2009-12-31 5.47x 0.30x 0.30x -9.43x -0.69x
2008-12-31 0.87x -0.18x 5.20x -73.21x -0.69x
2007-12-31 3.08x -0.01x 3.57x -161.57x -0.04x
2006-12-31 N/A N/A N/A -263.22x 0.00x
2005-12-31 N/A N/A N/A N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about OMER.US!